Login to Your Account



Other News To Note


Wednesday, November 23, 2011
• Amsterdam Molecular Therapeutics NV, of Amsterdam, the Netherlands, received orphan drug designation from the European Medicines Agency for its hemophilia B gene therapy. A Phase I/II trial is ongoing with the treatment, which consists of an adeno-associated viral vector containing the human factor IX gene.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription